Special Reports:

Our HIV reporting of the past decade

< Back to special reports

A large chunk of our reporting focuses on HIV. Since the launch of Bhekisisa in 2013, we’ve covered HIV in-depth — from the impact of the virus on former president Nelson Mandela’s family to the advances in antiretroviral treatment and anti-HIV pills and injections. We’ve also looked at the impact of inequality and discrimination on the spread of HIV, the link between gender-based violence and HIV — and ways to fix it.

HomeMultimedia #Aids2020 study: Dolutegravir doesn't pose a higher risk for birth defects....

Multimedia Videos Special Reports Our HIV reporting of the past decade

[WATCH] #Aids2020 study: Dolutegravir doesn’t pose a higher risk for birth defects. Here’s why

Laura López González and Dylan Bush

–

November 27, 2019

Laura López González and Dylan Bush

November 27, 2019

Dolutegravir is part of a three-in-one pill, and unlike other ARVs, can be taken on an empty stomach. Previously, it was thought to hold a risk of birth defects to babies when mothers with HIV fell pregnant while using the drug or used it during the early stages of pregnancy.

Laura López González

Laura Lopez Gonzalez is a freelance health journalist and editor. She was Bhekisisa's news editor, then deputy editor between 2016 and 2020.

Dylan Bush

Dylan Bush was a health journalist at Bhekisisa from February 2016 to September 2023.

Previous article

Risks & benefits: New HIV drug combo could change the course of SA’s epidemic

Next article

Romeo and Juliet are sexting: Will SA’s new sex-ed prepare children for life, love and lust?

RELATED ARTICLES

MORE FROM AUTHOR

Archives